Orphan Drug Designation of FDA and Compliance Services

Overview of the Orphan Drug Framework

In the United States, an "orphan drug" is a biological product or medicine intended to treat, prevent, or diagnose a rare disease or condition. According to the Orphan Drug Act, a rare disease is defined as one affecting fewer than 200,000 individuals in the U.S., or a condition affecting more than 200,000 people where there is no reasonable expectation that the cost of developing the drug will be recovered from sales. To stimulate research in these underserved areas, the FDA provides a robust set of financial and regulatory incentives through the Office of Orphan Products Development (OOPD).

Key Incentives for Obtaining ODD

Securing an Orphan Drug Designation offers significant strategic advantages that reduce the financial burden and time-to-market for innovative therapies:

• Seven-Year Market Exclusivity

Upon regulatory approval, the sponsor enjoys seven years of exclusive marketing rights, during which the FDA will not approve the same drug for the same rare indication.

• Tax Credits for Clinical Testing

Sponsors can claim a 25% tax credit for qualified clinical testing expenses incurred in the U.S., directly subsidizing research costs.

• Waiver of Prescription Drug User Fees

ODD status allows manufacturers to bypass the substantial PDUFA application fees, often saving millions of dollars per submission.

• Access to Federal Grants

Designated products are eligible to apply for specialized FDA grants to fund Phase I, II, or III clinical trials.

• Enhanced Regulatory Guidance

The FDA provides frequent opportunities for meetings and specialized advice on clinical protocol design and accelerated approval pathways like Fast Track.

The ODD Application and Submission Process

The application for Orphan Drug Designation is a technical undertaking that requires rigorous scientific evidence to prove the drug's potential efficacy and the rarity of the target condition. Our team manages the entire lifecycle of the submission to ensure it meets the FDA's stringent criteria.

Critical Stages of Review

• Formal Submission: Applications are submitted electronically. The FDA typically acknowledges receipt and begins a preliminary check for administrative completeness.
• The 90-Day Review Cycle: The standard review timeframe for an ODD application is 90 days, during which the FDA evaluates the scientific merits and prevalence data.
• Post-Designation Maintenance: Once granted, sponsors are required to submit annual reports to update the FDA on the progress of the drug's development and any changes in its safety profile.

Why Partner with Proregulations?

We provide a comprehensive bridge between pharmaceutical innovation and international regulatory standards. Our core service modules include:

• Strategic ODD feasibility assessment
  We evaluate your drug's mechanism of action and clinical data to determine if it meets the legal definition of an orphan product.
• Prevalence and epidemiological research
  Using authoritative databases, we provide the documented proof required to verify that the target population in the U.S. remains under the 200,000-person threshold.
• Comprehensive dossier preparation
  Our experts draft the complete application package, including the formal Cover Letter, Form 3615, and the detailed scientific narrative describing the disease and the drug's rationale.
• FDA liaison and query management
  We serve as the primary contact with the OOPD, responding to "Information Requests" and managing all correspondence throughout the review period.

If you are interested in our U.S. Orphan Drug Designation application services and wish to accelerate your path to market for a rare disease therapy, please feel free to contact us.